Hims & Hers Health raised FY2026 revenue guidance to $2.8-$3.0 billion despite reporting a heavily distorted quarterly EPS loss. More than 125,000 Wegovy shipments in six weeks suggest Novo conversion ...
Hims & Hers Health, Inc. is facing existential risk as regulatory uncertainty and margin erosion undermine its growth narrative. HIMS' reliance on compounded GLP-1 drugs has faltered, with regulatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results